Table 5.
Optic nerve regeneration: cell therapy clinical trials for optic nerve disorders.
| Reference | Disease | Cell Type | Administration Route | Sponsor | Study Start Date | Status |
|---|---|---|---|---|---|---|
| NTC 02638714 Phase I/II Study |
Optic nerve atrophy | Autologous bone marrow CD 34+, 133+, and 271+ stem cells |
No site declared | Stem Cells Arabia | April 2013 | Recruiting |
| NTC 03173638 Phase II Study |
Acute ischemic optic neuropathy nonarteritic | Allogenic mesenchymal stem (MSV) cells from bone marrow | Intravitreal injection | IOBA, Spain | March 2018 | Recruiting |
| NCT 022836771 Phase I Study |
Neuromyelitis optica | Tolerogenic dendritic cells loaded with myelin peptides | Intravenous administration | Hospital Clinic of Barcelona, Spain | September 2015 | Completed |
| NTC 01920867 Phase (n/a) |
Various ocular diseases including optic neuritis | Bone marrow derived stem cells (BMSC). Study I | Injections of BMSC retrobulbar, subtenon and intravenous | MD Stem Cells, USA | August 2012 | Enrolling by invitation |
| NTC 03011541 Phase (n/a) |
Various ocular diseases including optic neuropathy Nonarteritic ischemic optic neuropathy Optic atrophy, optic nerve disease, glaucoma, Leber hereditary optic neuropathy |
Bone marrow derived stem cells (BMSC). Study II | Injections of BMSC retrobulbar, subtenon and intravenous | MD Stem Cells, USA | January 2016 | Recruiting |
| NTC 00787722 Phase I/II Study |
Devic neuromyelitis | High dose immunosuppressive therapy with hematopoietic stem cells transplantation | Intravenous infusion | Northwestern University, USA | October 2009 | Completed |
| NTC 00716066 Phase II Study |
Neurologic autoimmune diseases, including neuromyelitis optica | High dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation | Intravenous infusion | Fred Hutchinson Cancer Research Center National Cancer Institute, USA |
June 2008 | Recruiting |
| NTC 04577300 Phase II Study |
Glaucoma | Dual NT-501 CNTF encapsulated cell therapy | Intravitreal NT-501 implants | Stanford University, USA | October 2020 | Not yet recruiting |
| NTC 02862938 Phase II Study |
Glaucoma | NT-501 CNTF encapsulated cell therapy | Intravitreal NT-501 implants | Stanford University, USA | August 2016 | Active, not recruiting |
| NTC 02330978 Phase I Study |
Glaucoma | Autologous bone marrow-derived mesenchymal stem cell | Intravitreal | University of Sao Paulo, Brazil | July 2019 | Completed |
(n/a): not applicable; (CNTF): soluble ciliary neurotrophic factor.